EGFR Mutation Analysis of Circulating Tumor DNA Using an Improved PNA-LNA PCR Clamp Method

Table 1

Patients’ characteristics.

	EGFR mutant (biopsy sample)	EGFR mutant (biopsy sample)		Wild-type EGFR (biopsy sample)
		Plasma EGFR mut+	Plasma EGFR mut−
Total,	24	19	5	6
Age
Median (range)	67 (46–87)	67 (46–87)	68 (55–84)	70 (64–79)
Gender
Female	16 (66.7)	11 (57.9)	5 (100)	1 (16.7)
Male	8 (33.3)	8 (42.1)	0 (0.0)	5 (83.3)
Smoking status
Never	18 (75%)	14 (73.7)	4 (80.0)	2 (33.3)
Former	3 (12.5)	2 (10.5)	1 (20.0)	1 (16.7)
Current	3 (12.5)	3 (15.8)	0 (0.0)	3 (50.0)
ECOG PS
0	8 (33.3)	5 (26.3)	3 (60.0)	1 (16.7)
1	14 (58.3)	12 (63.2)	2 (40.0)	5 (83.3)
2	2 (8.3)	2 (10.5)	0 (0.0)	0 (0.0)
Stage
IIA	0 (0.0)	0 (0.0)	0 (0.0)	1 (16.7)
IIIA	2 (8.3)	1 (5.3)	1 (20.0)	1 (16.7)
IV	22 (91.7)	18 (94.7)	4 (80.0)	4 (66.7)
IV-M1a	8 (36.4)	4 (22.2)	4 (100)	1 (16.7)
IV-M1b	14 (63.6)	14 (77.8)	0 (0.0)	3 (50.0)
Tumor EGFR mutation status
Wild type	0	0	0	6 (100)
del19	15 (62.5)	12 (63.2)	3 (60.0)	0
L858R	8 (33.3)	7 (36.8)	1 (20.0)	0
L861Q	1 (4.2)	0 (0.0)	1 (20.0)	0